CMSHealth Care - GeneralHealth InsuranceMedicare - GeneralPart D/Prescription Drugs

Novo’s Ozempic Seen as Shoo-In for Next Round of Medicare Price Negotiations

By Greg Slabodkin for BioSpace on Septermber 25, 2024

Novo Nordisk’s blockbuster type 2 diabetes medication is a sure bet for the list of the next 15 drugs whose Medicare prices will be negotiated in 2025 and go into effect in 2027, according to analysts and academics. Here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org